COMMUNIQUÉS West-GlobeNewswire

Aeroponics Can Change Cannabis Cultivation -- CFN Media

27/07/2018 - 15:00

SEATTLE, July 27, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering [...]

BlissCo Advances E-Commerce Program Ahead of Cannabis Legalization -- CFN Media

27/07/2018 - 15:00

SEATTLE, July 27, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing [...]

ContraFect Corporation Prices $10 Million Public Offering of Common Stock

27/07/2018 - 15:00

YONKERS, N.Y., July 27, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug- [...]

BioCryst to Announce Second Quarter 2018 Financial Results on August 7

27/07/2018 - 15:00

RESEARCH TRIANGLE PARK, N.C., July 27, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that its second quarter 2018 financial results will be reported on Tuesday, August 7, 2018. [...]

Sandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab)

27/07/2018 - 14:54

Biosimilar Hyrimoz ® (adalimumab) approved for use in all same indications as reference medicine ** * including rheumatology, gastroenterology and dermatology Early therapeutic intervention is essential in rheumatoid [...]

Curriculum Vitae of Lauris Macijevskis a newly elected Board member of AS Olainfarm

27/07/2018 - 14:45

CURRICULUM VITAE of Lauris Macijevskis Name, Surname: Lauris Macijevskis Education: 2004 - 2006 Riga International School of Economics and Business Administration, diploma for higher professional education - Master in [...]

Cellectar Biosciences Announces Pricing of $14.4 Million Underwritten Public Offering

27/07/2018 - 14:30

MADISON, Wis., July 27, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB) (“Cellectar” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization [...]

Ultragenyx to Host Conference Call for Second Quarter 2018 Financial Results and Corporate Update

27/07/2018 - 14:30

NOVATO, Calif., July 27, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced [...]

Tetraphase Pharmaceuticals Receives Positive CHMP Opinion for Xerava™ (eravacycline) as a Treatment for Complicated Intra-Abdominal Infections

27/07/2018 - 14:30

WATERTOWN, Mass., July 27, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening [...]

CHMP Issues Positive Opinion Recommending DARZALEX® (daratumumab) for Front Line Multiple Myeloma

27/07/2018 - 14:28

Company Announcement CHMP issued positive opinion for DARZALEX for front line multiple myeloma Final decision from European Commission expected in the coming months Opinion based on data from Phase III ALCYONE study [...]

Novartis combination Tafinlar® + Mekinist® receives positive CHMP opinion for adjuvant treatment of BRAF V600 mutation-positive melanoma

27/07/2018 - 14:25

Phase III trial showed a 53% reduction in risk of recurrence or death with the combination of a BRAF and MEK inhibitor as adjuvant therapy versus placebo[1] Relapse-free survival benefit with Tafinlar + Mekinist [...]

Status of the Market Authorisation Application of Apealea in the European Union

27/07/2018 - 14:25

Oasmia Pharmaceutical AB hereby issues a notification that contrary to what was anticipated in the draft agenda for this month’s meeting by the Committee for Medicinal Products for Human Use (CHMP), there was no oral [...]

European CHMP Maintains Negative Opinion on Portola Pharmaceuticals’ Betrixaban Following Appeal

27/07/2018 - 14:24

SOUTH SAN FRANCISCO, Calif., July 27, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq:PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines [...]

Sun Biopharma, Inc. Presents Poster at Pancreasfest in Pittsburgh, Pa.

27/07/2018 - 14:00

Results of Phase 1 Safety Study of SBP-101 for Pancreatic Ductal Adenocarcinoma PancreasFest is an International Conference of Physicians and Scientists Focused on Pancreatic Diseases MINNEAPOLIS, MN, July 27, 2018 ( [...]

Delcath Amends Phase 3 Ocular Melanoma Trial Protocol

27/07/2018 - 14:00

Revision to Nonrandomized (Single Arm) Study Reduces Trial Size Enrollment Requirement Enrollment Anticipated to be Completed by First Half 2019 NEW YORK, July 27, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: [...]

Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 HONOR Study of Tonmya® in Military-Related PTSD

27/07/2018 - 14:00

HONOR Study will Stop due to Inadequate Separation from Placebo at Week-12 Results at Week-4 Demonstrated Meaningful Clinical Improvement Company Plans to Meet with FDA to Discuss Next Steps for this Breakthrough [...]

Samumed Presents Positive Preclinical Data on SM07883 at 2018 Alzheimer’s Association International Conference® (AAIC®)

27/07/2018 - 14:00

Data supports SM07883 as a potential treatment for chronic tauopathies such as Alzheimer’s disease Company expects SM07883 to enter first-in-man studies in fall 2018 SAN DIEGO, July 27, 2018 (GLOBE NEWSWIRE) -- Samumed [...]

eFFECTOR Initiates Dosing of eFT508 (tomivosertib) in a Phase 2 Add-on (CPI-A) Trial in Combination with Checkpoint Inhibitors to Treat Patients with Insufficient Response to Checkpoint Inhibitors Alone

27/07/2018 - 13:30

SAN DIEGO, July 27, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that it has dosed the first [...]

BeiGene Announces Proposed Hong Kong Initial Public Offering and Global Offering

27/07/2018 - 13:08

CAMBRIDGE, Mass. and BEIJING, China, July 27, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted [...]